**Abstract**

It has widely been accepted that D-serine plays a pivotal role in the regulation of glutamate neurotransmission as an endogenous co-agonist for the N-methyl-D-aspartate-type glutamate receptor (NMDAR). Consequently, the putative NMDAR dysregulation in the pathophysiology of schizophrenia and mood disorders could be due to disturbed D-serine signaling. Some studies described the changed D-serine levels in serum, plasma and cerebrospinal fluid (CSF) of patients with schizophrenia and major depressive disorder (MDD). Furthermore, G72 gene that encodes an activator protein of D-amino acid oxidase (DAAO), a D-serine degrading enzyme, has been reported to associate with schizophrenia and bipolar disorders. To further elucidate the relationship between D-serine metabolism and psychiatric disorders, we presently examined by an ELISA technique the contents of G72 protein in plasma and CSF of Japanese patients with schizophrenia, MDD, and healthy controls. Neither plasma nor CSF G72 protein levels differ among the three diagnostic groups and relate with age of the participants in each group. These data do not support the previously observed distinct expression in plasma or CSF G72 protein levels in schizophrenia. On the other hand, we found a significant positive correlation between plasma G72 protein levels and the positive score (P=0.027, r=0.43) of the Positive and Negative Syndrome Scale (PANSS), but not the PANSS negative, general psychopathology or total scores, in the patients with schizophrenia. The CSF G72 protein levels did not significantly correlate with each of the four PANSS scores. In MDD, there was no significant association of either of plasma or CSF G72 levels with depression severity scores. To obtain an insight into the significance of the above correlation in schizophrenia, further studies to clarify the molecular and cellular mechanisms and extrinsic factors of the control of G72 expression are required.
